Screener
Supernus Pharmaceuticals SUPN Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income (expense) | ||
| Interest and other income, net | 2,382 | 4,425 |
| Total other income (expense), net | 2,382 | 4,425 |
| Loss before income taxes | (5,950) | (5,831) |
| Income tax expense (benefit) | (3,657) | 5,996 |
| Net loss | $(2,293) | $(11,827) |
| Loss per share | ||
| Basic | $(0.04) | $(0.21) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's pre-tax income?
- Supernus Pharmaceuticals (SUPN) reported pre-tax income of -$5.95M in Q1 2026.
- How has Supernus Pharmaceuticals's pre-tax income changed year-over-year?
- Supernus Pharmaceuticals's pre-tax income decreased by 2.0% year-over-year, from -$5.83M to -$5.95M.
- What is the long-term trend for Supernus Pharmaceuticals's pre-tax income?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's pre-tax income has grown at a -9.5% compound annual growth rate (CAGR), from $73.18M to -$49.03M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Supernus Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude